14-day Premium Trial Subscription Try For FreeTry Free
$8.50
-0.1000 (-1.16%)
At Close: May 06, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $5.34 $19.02 Monday, 6th May 2024 OTLK stock ended at $8.50. This is 1.16% less than the trading day before Friday, 3rd May 2024. During the day the stock fluctuated 5.44% from a day low at $8.45 to a day high of $8.91.
90 days $17.30 $19.02
52 weeks $16.32 $20.85

Historical Outlook Therapeutics Inc. prices

Date Open High Low Close Volume
Dec 11, 2023 $0.430 $0.436 $0.420 $0.429 871 782
Dec 08, 2023 $0.437 $0.437 $0.422 $0.426 880 002
Dec 07, 2023 $0.450 $0.450 $0.435 $0.442 869 154
Dec 06, 2023 $0.450 $0.451 $0.436 $0.445 1 195 160
Dec 05, 2023 $0.430 $0.459 $0.430 $0.449 1 116 042
Dec 04, 2023 $0.390 $0.460 $0.390 $0.437 1 752 451
Dec 01, 2023 $0.475 $0.480 $0.457 $0.473 1 606 112
Nov 30, 2023 $0.469 $0.485 $0.469 $0.480 1 105 079
Nov 29, 2023 $0.480 $0.486 $0.465 $0.480 2 434 399
Nov 28, 2023 $0.477 $0.498 $0.471 $0.484 1 339 204
Nov 27, 2023 $0.465 $0.482 $0.451 $0.472 2 008 735
Nov 24, 2023 $0.451 $0.461 $0.450 $0.460 1 505 255
Nov 22, 2023 $0.443 $0.460 $0.422 $0.451 2 332 542
Nov 21, 2023 $0.432 $0.434 $0.416 $0.430 774 724
Nov 20, 2023 $0.460 $0.464 $0.380 $0.440 2 302 683
Nov 17, 2023 $0.442 $0.469 $0.430 $0.460 1 980 969
Nov 16, 2023 $0.448 $0.450 $0.421 $0.436 1 807 238
Nov 15, 2023 $0.440 $0.453 $0.432 $0.446 1 480 577
Nov 14, 2023 $0.422 $0.440 $0.411 $0.440 1 247 165
Nov 13, 2023 $0.395 $0.409 $0.394 $0.404 1 255 122
Nov 10, 2023 $0.445 $0.445 $0.390 $0.400 2 835 422
Nov 09, 2023 $0.490 $0.500 $0.441 $0.445 3 263 272
Nov 08, 2023 $0.500 $0.535 $0.464 $0.500 4 498 554
Nov 07, 2023 $0.443 $0.530 $0.443 $0.507 9 406 096
Nov 06, 2023 $0.458 $0.466 $0.432 $0.448 5 738 606
Click to get the best stock tips daily for free!

About Outlook Therapeutics Inc.

Outlook Therapeutics. Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and lice... OTLK Profile

Golden Star

Ticker Date Change Price
TMO May 02 0.403% $571.25
STNG May 02 0.699% $71.50
DLR May 02 2.58% $140.15
RF May 02 0.97% $19.64
INVH May 02 0.87% $34.50
SMAR May 02 2.24% $38.39
BIRK May 02 0.650% $44.61
FTSL May 02 0.217% $46.11
VCSH May 02 0.287% $76.71
VRNT May 02 2.44% $30.78
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT